Cartesian Therapeutics, Inc.RNACNASDAQ

|||

Switch Symbol:

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 86% recommend buying.

Consensus Rating

Buy

7 analysts·Limited coverage

86%

Rating Distribution

Strong Buy

00%

Buy

686%

Hold

114%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 516% higher.

Bear Case

$40.00

+477%

Consensus

$42.67

+516%

Bull Case

$45.00

+549%

Price Range7 analysts

Low

Consensus

High

$40.00

$45.00

Current Target

Current Price

$6.93

Upside to Target

$35.74

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-3.37(5 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+10.26%

EPS—

FY2028

Rev+3149.95%

EPS—

FY2029

Rev+275.42%

EPS—

Earnings Surprises

Beat rate:58%(7/12 quarters)

Avg surprise:-30.8%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Aug 9, 2024H.C. Wainwright

Cartesian Therapeutics price target lowered to $45 from $49 at H.C. Wainwright

Target:$45.00

+249.7%from $12.87

Jul 3, 2024Canaccord Genuity

Cartesian Therapeutics price target raised to $43 from $38 at Canaccord

Target:$43.00

+172.7%from $15.77

May 24, 2024Mizuho Securities

Mizuho Resumes Cartesian Therapeutics (RNAC) at Buy

Target:$40.00

+57.1%from $25.46

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance